Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Latest filing published 02 Dec 2022 for Magenta Therapeutics, Inc., €2,731. Read the official filing
Filing timeline
BuySaleJason Gardner
Insider track record
Disclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Jason Gardner: trading record in brief
All filings by Jason Gardner on record concern Dianthus Therapeutics, Inc. /DE/. Over a trading history stretching from 14 September 2021 to 30 November 2022, the count stands at 4 filings.
No open-market purchase appears, only 1 sale worth €82k. Besides market trades, the filings include 3 share grants.
Most recently, on 2 December 2022, the filings show a share grant worth €2,731 in Dianthus Therapeutics, Inc. /DE/. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Jason Gardner
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
3,000 shares@ US$0.941.6% of flowCommon StockSEC:0000899243-22-037431:0
3,000 shares@ US$0.993.2% of flowCommon StockSEC:0000899243-22-021184:0
14,340 shares@ US$6.7393.7% of flowCommon StockSEC:0000899243-21-036599:0
50,000 shares0Common StockSEC:0000899243-21-036335:0
4 of 4 declarations
